Macrocycles
Macrocycles, with their cyclic structures, show potential for targeting diverse protein sites, though challenges remain in optimizing oral dosing and intracellular delivery.

Orbis Medicines is a biotechnology company discovering oral macrocycle drugs using nGen to integrate generative AI with high-throughput synthetic chemistry.
orbismedicines.comCrawled Nov 3, 2026
Macrocycles, with their cyclic structures, show potential for targeting diverse protein sites, though challenges remain in optimizing oral dosing and intracellular delivery.
Base to Base Biotech by Jim Cornall Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.
Drug Target Review New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
The Bio Report Orbis Medicines is developing orally available synthetic macrocycles called n Cycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology .
European Biotechnology explores how macrocycles—large, ring-shaped molecules—bridge traditional small molecules and biologics to improve drug selectivity and effectiveness.
Pharmaceutical Executive reports that Morten Graugaard discussed FDA approval of Icotyde as a milestone for developing oral biologics with accessible formats.
BiotechTV CEO Morten Graugaard discusses the limitations of previous generations of macrocycles and describes what he believes the power is behind the Orbis platform.
Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark’s first AI supercomputer, Gefion, which is owned and operated by DCAI.
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases.
Pharma Boardroom As pharmaceutical companies race to replace injectable therapies with more accessible oral biologics, Orbis Medicines is leading the charge with its next-generation macrocycle platform and AI-powered discovery engine.
Orbis combines scientific innovation, trust, and shared ownership to advance medical breakthroughs through collaborative teamwork.
Orbis Medicines names **Joanne Smith-Farrell, Ph.D.** as CEO to accelerate its **AI-driven oral macrocycle drug platform** and expand its development pipeline. The company also strengthens its partnership with **Novo Nordisk**, which includes a collaboration valued at up to **$1.4 billion**. Smith-Farrell’s leadership focuses on scaling Orbis’s proprietary technology and advancing clinical-stage programs.
Orbis Medicines partners with Novo Nordisk in a multi-target drug discovery collaboration valued at up to **USD 1.4 billion**. The agreement includes upfront payments, future milestone payments, and tiered royalties. Both companies will jointly advance research in novel therapeutic approaches targeting multiple disease mechanisms.
Orbis Medicines deploys Denmark’s first AI supercomputer, Gefion, to advance its oral macrocycle drug platform. The system enhances computational drug discovery by integrating AI-driven simulations and modeling. This move aims to streamline the development of novel, orally bioavailable macrocyclic compounds for therapeutic use.
Orbis Medicines appoints **Mikael Dolsten** as its new **Board Chair**. Dolsten brings extensive biopharma leadership experience, most recently as **Chief Scientific Officer (CSO) of Pfizer**, and previously held senior roles at **AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals**. His appointment strengthens Orbis Medicines’ governance with decades of R&D expertise in drug development.
Orbis Medicines secures **EUR 90 million in Series A funding** to advance its pipeline of **oral macrocycle drugs**, targeting validated blockbuster biologics. The company’s platform, named **nCycles**, aims to deliver small-molecule alternatives to high-value biologics. This capital supports preclinical and clinical development of its lead programs.
Orbis Medicines secures €26 million in seed funding led by Novo Holdings and Forbion to develop orally dosable macrocycle drugs. The company combines high-throughput chemical synthesis, large-scale assaying, and machine learning to explore macrocycle chemical space systematically. Its pipeline targets high-value oral alternatives to blockbuster biologic drugs and unlocks new therapeutic opportunities.